{
    "clinical_study": {
        "@rank": "119413", 
        "acronym": "CSPS\u30fbcom", 
        "arm_group": [
            {
                "arm_group_label": "Monotherapy group", 
                "arm_group_type": "Active Comparator", 
                "description": "Aspirin (81mg or 100mg) or clopidogrel (50mg or 75mg) will be orally administered once daily.\nThe treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
            }, 
            {
                "arm_group_label": "DAPT group", 
                "arm_group_type": "Experimental", 
                "description": "Cilostazol (100mg twice daily) will be orally administered in combination with aspirin (81 or 100mg once daily) or clopidogrel (50 or 75mg once daily).\nThe treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
            }
        ], 
        "brief_summary": {
            "textblock": "To examine the efficacy and safety of dual antiplatelet therapy (DAPT) including cilostazol\n      (Pletaal OD Tablet \u00ae) in comparison with antiplatelet monotherapy (excluding cilostazol) for\n      secondary prevention of ischemic stroke in high-risk patients for stroke"
        }, 
        "brief_title": "Cilostazol Stroke Prevention Study for Antiplatelet Combination", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Noncardioembolic Cerebral Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Cerebral Infarction", 
                "Stroke", 
                "Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a diagnosis of noncardioembolic IS that developed between 8 and 180\n             days before the start of the protocol treatment\n\n          -  Patients with a responsible lesion  identified by MRI\n\n          -  Patients aged 20 to 85 years old when providing informed consent\n\n          -  Patients taking clopidogrel or aspirin alone as antiplatelet therapy when providing\n             informed consent\n\n          -  Patients meeting at least one of the following criteria a\u2212c:\n\n               1. at least 50% stenosis of a major intracranial artery (to the level of A2, M2, or\n                  P2)\n\n               2. at least 50% stenosis of an  extracranial artery (the common carotid\n                  artery\uff0cinternal carotid artery\uff0cvertebral artery\uff0cbrachiocephalic artery\uff0cor\n                  subclavian artery)\n\n               3. Two or more of the following risk factors\n\n                    -  Aged 65 years or more\n\n                    -  Diabetes mellitus\n\n                    -  Hypertension\n\n                    -  Peripheral arterial disease\n\n                    -  Chronic kidney disease\n\n                    -  History of IS (excluding the index IS for this study)\n\n                    -  History of ischemic heart disease\n\n                    -  Smoking (only current smokers)\n\n          -  Patients considered to be able to visit the study site for ambulatory care throughout\n             the observation period\n\n          -  Patients who provided written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with emboligenic heart disease\n\n          -  Patients taking any anticoagulant agents\n\n          -  Patients who cannot undergo MRI examination for reasons such as claustrophobia and\n             implanted pacemaker\n\n          -  Patients scheduled to undergo any surgery, such as percutaneous angioplasty, stent\n             placement, and bypass grafting, during the study period\n\n          -  Patients with a drug-eluting coronary stent implanted within one year\n\n          -  Patients with a history of symptomatic non-traumatic intracranial hemorrhage, any\n             other hemorrhagic disease (eg, active peptic ulcer), bleeding predisposition,  or\n             blood clotting disorders\n\n          -  Patients with a history of hypersensitivity to cilostazol\n\n          -  Patients with congestive heart failure or uncontrolled angina pectoris\n\n          -  Patients with thrombocytopenia (platelet count \u2266 100,000/mm3)\n\n          -  Patients with severe liver or renal dysfunction\n\n          -  Women who are pregnant, breast-feeding, or of child-bearing potential\n\n          -  Patients with a malignant tumor requiring treatment\n\n          -  Patients who are taking aspirin, and meet any of the following criteria:\n\n               -  History of hypersensitivity to aspirin or salicylic acid analogues\n\n               -  Current peptic ulcer\n\n               -  Aspirin-induced asthma or its history\n\n          -  Patients who are taking clopidogrel, and meet the following criterion:\n\n             \u30fbHistory of hypersensitivity to clopidogrel\n\n          -  Patients who are participating in any other clinical studies\n\n          -  Patients considered by the investigator/subinvestigator to be unsuitable for\n             participating in this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "4000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995370", 
            "org_study_id": "021-TADD-1300-1", 
            "secondary_id": "000012180"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Monotherapy group", 
                    "DAPT group"
                ], 
                "description": "Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.", 
                "intervention_name": "aspirin", 
                "intervention_type": "Drug", 
                "other_name": "Bayaspirin"
            }, 
            {
                "arm_group_label": [
                    "Monotherapy group", 
                    "DAPT group"
                ], 
                "description": "Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.", 
                "intervention_name": "clopidogrel", 
                "intervention_type": "Drug", 
                "other_name": "Plavix"
            }, 
            {
                "arm_group_label": "DAPT group", 
                "description": "Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.", 
                "intervention_name": "cilostazol", 
                "intervention_type": "Drug", 
                "other_name": "Pletaal OD Tablet"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Cilostazol", 
                "Clopidogrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Noncardioembolic cerebral infarction", 
            "Dual antiplatelet therapy (DAPT)", 
            "Cilostazol", 
            "Aspirin", 
            "Clopidogrel"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "jcrf-csps@jcvrf.jp", 
                "last_name": "Norio Aso", 
                "phone": "+81-6-6872-0010"
            }, 
            "contact_backup": {
                "email": "prj-csps.cont.com@eps.co.jp", 
                "last_name": "Minoru Ido", 
                "phone": "+81-6-4807-3015"
            }, 
            "facility": {
                "address": {
                    "city": "Osaka", 
                    "country": "Japan", 
                    "zip": "565-8565"
                }, 
                "name": "Japan Cardiovascular Research Foundation"
            }, 
            "investigator": {
                "last_name": "Takenori Yamaguchi", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Cilostazol Stroke Prevention Study for Antiplatelet Combination", 
        "overall_contact": {
            "email": "jcrf-csps@jcvrf.jp", 
            "last_name": "Norio  Aso", 
            "phone": "+81-6-6872-0010"
        }, 
        "overall_contact_backup": {
            "email": "prj-csps.cont.com@eps.co.jp", 
            "last_name": "Minoru Ido", 
            "phone": "+81-6-4807-3015"
        }, 
        "overall_official": {
            "affiliation": "National Cerebral and Cardiovascular Center", 
            "last_name": "Takenori Yamaguchi, President emeritus", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "An \"ischemic stroke\" hereafter indicates a symptomatic ischemic stroke.", 
            "measure": "Recurrence of symptomatic ischemic stroke, with the symptoms lasting for at least 24 hours", 
            "safety_issue": "No", 
            "time_frame": "every 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995370"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Any stroke [ischemic stroke (IS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH)]", 
                "safety_issue": "No", 
                "time_frame": "every 6 months"
            }, 
            {
                "measure": "SAH or ICH", 
                "safety_issue": "No", 
                "time_frame": "every 6 months"
            }, 
            {
                "measure": "IS or transient ischemic attack (TIA)", 
                "safety_issue": "No", 
                "time_frame": "every 6 months"
            }, 
            {
                "measure": "Death from any cause", 
                "safety_issue": "No", 
                "time_frame": "every 6 months"
            }, 
            {
                "measure": "Stroke (IS\uff0cICH\uff0cSAH), myocardial infarction (MI), or vascular death", 
                "safety_issue": "No", 
                "time_frame": "every 6 months"
            }, 
            {
                "measure": "All vascular events: stroke, MI, and other vascular events", 
                "safety_issue": "No", 
                "time_frame": "every 6 months"
            }, 
            {
                "measure": "Adverse events and adverse drug reactions", 
                "safety_issue": "Yes", 
                "time_frame": "every 6 months"
            }, 
            {
                "measure": "Severe or life-threatening hemorrhage (GUSTO Criteria)", 
                "safety_issue": "Yes", 
                "time_frame": "every 6 months"
            }
        ], 
        "source": "Japan Cardiovascular Research Foundation", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Japan Cardiovascular Research Foundation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}